"One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases." (Company Website)
Over the last three presidential administrations, the United States government has granted Genzyme Corporation 14 special licenses to do business in Iran. (New York Times, "Companies with Permission to Bypass Sanctions," 12/24/10)
Website states that it does business with Iran and other Middle Eastern countries through its Dubai office.
Genzyme Middle East (Company Website)
The Dubai office will provide regional sales and marketing support to customers and distributors for its enzyme replacement treatments for Gaucher, MPS I, Fabry and Pompe, four Lysosomal Storage Diseases*. It will also support activities for Renagel, a treatment to reduce the phosphorus levels in chronic kidney disease patients on hemodialysis, Thymoglobulin, an immunosuppressant for treating and preventing acute rejection in renal transplant patients, and Thyrogen, an adjunct to thyroid cancer disease management designed to aid in the treatment and earlier detection of recurrence…
The Dubai office will represent Genzyme in Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Qatar. Further activities in Yemen, Syria and Sudan could be foreseen.” (AMEinfo.com, “Genzyme inaugurates Middle East office in Dubai,” 11/6/06)